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OBJECTIVES: Herd immunity describes a phenomenon in the area of communicable 
diseases. Pathogens are spread by infected persons. Protecting a part of the popula-
tion—for example via vaccination—lowers the overall appearance of pathogens as 
these people cannot spread pathogens any more. Not protected people profi t by fewer 
contacts with pathogens, and further, a lower number of infections for them can be 
expected. Classic Markov model cannot provide herd immunity as a result. In this 
work, we propose calculations of herd immunity, create a model that is able to simu-
late epidemics, and show herd immunity dynamically in different states of the model. 
Appearance of herd immunity is very disputed because it 1) cannot be measured 
directly in real life and 2) depends on several factors. METHODS: Classic Markov 
models require herd immunity as a static input parameter that cannot be provided. 
The developed agent-based model includes single persons with different infection 
states and a single pathogen. Every agent is part of a social contact model. It is possible 
to simulate scenarios without vaccinations and with different vaccination strategies. 
Herd immunity as a result of the dynamic model is calculated as the reduction of the 
carrier rate of nonvaccinated persons for a certain vaccination strategy compared with 
the scenario without vaccinations. RESULTS: Results show herd immunity as simula-
tion result depending not only on vaccination strategies but also on other system 
parameters. Further work extends the social contact structure with places like house-
holds, schools, or workplaces that are expected to have an impact on herd immunity 
as well. CONCLUSIONS: Results can be implemented in systems for calculating new 
strategies for vaccination programs. Current work considers two or more concurrent 
serotypes where herd immunity and serotype replacement affects each other. In this 
case, different defi nitions of herd immunity are possible.
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OBJECTIVES: Acute myeloid leukemia (AML) is a heterogeneous disease, consisting 
of several subtypes with a variety in prognosis. a new genomics technology, the AML 
profi ler, has been developed that identifi es new genetic subtypes. Since no decision 
model exists that describes the full disease course of AML, the potential cost-effec-
tiveness of this test cannot yet be determined. The aim of this study is to fi ll this gap 
and develop and validate a disease progression model for AML. METHODS: The 
structure of the model and the identifi cation of relevant parameters were based on the 
literature and expert opinion. All input parameters were estimated from clinical trial 
data (HOVON data) for patients aged 18 to 60 years. The internal and external 
validity of the model was evaluated by comparing model-based survival results with 
the results from HOVON trials and the literature. RESULTS: Important prognostic 
factors for AML were derived from the literature and expert opinion a microsimula-
tion model (i.e., individual patient sampling) was designed to incorporate all important 
prognostic factors in the model. The prognostic factors were included as covariates in 
parametric survival functions for two events: relapse and death. The model combined 
those survival functions with individual patient data to calculate life-years per patient. 
The average 5-year survival of the simulated patient cohort was 40%, which is similar 
to the survival found in HOVON trials and the literature. DISCUSSION: The content 
validity of the model was achieved by involving clinical experts in the construction of 
the model. The survival estimated using the model corresponds with those seen else-
where, suggesting an acceptable level of internal and external validity. Therefore, the 
model can be used to assess the cost-effectiveness of AML genomics technologies such 
as the AML profi ler. Moreover, the model can be used for other cost-effectiveness 
analyses in the fi eld of AML.
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OBJECTIVES: We propose to combine the versatility of the analytic hierarchy process 
(AHP) with the decision-analytic sophistication of health-economic modeling in a new 
methodology for early technology assessment. As an illustration, we apply this meth-
odology to a new technology to diagnose breast cancer. METHODS: The AHP is a 
technique for multicriteria analysis, relatively new in the fi eld of technology assess-
ment. It can integrate both quantitative and qualitative criteria in the assessment of 
alternative technologies. We applied the AHP to prioritize a more versatile set of 
outcome measures than most Markov models do. These outcome measures include 
clinical effectiveness and costs, but also weighted estimates of patient comfort and 
safety. Furthermore, as no clinical data are available for this technology yet, the AHP 
is applied to predict the performance of the new technology with regard to all these 
outcome measures. Results of the AHP are subsequently integrated in a Markov model 
to make an early assessment of the expected incremental cost-effectiveness of alterna-
tive technologies. RESULTS: We systematically estimated priors on the clinical effec-
tiveness and wider impacts of the new technology using AHP. In our illustration, AHP 
estimates for sensitivity and specifi city of the new diagnostic technology were used as 
probability parameters in the Markov model. Moreover, the prioritized outcome 
measures including clinical effectiveness (weight = 0.61), patient comfort (weight = 
0.09), and safety (weight = 0.30) were integrated into one outcome measure in the 
Markov model. CONCLUSIONS: Combining AHP and Markov modelling is particu-
larly valuable in early technology assessment when evidence about the effectiveness 
of health care technology is still limited or missing. Moreover, combining these 
methods is valuable when decision makers are interested in other patient relevant 
outcomes measures besides the technology’s clinical effectiveness, and that may not 
(adequately or explicitly) be captured in mainstream utility measures. 
PODIUM SESSION I: RISK-SHARING SCHEMES
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OBJECTIVES: To develop a fi nancial risk forecasting model that could be used to 
negotiate risk-sharing schemes (RSS) conditions. RSS are increasingly being established 
as a market access strategy and have direct fi nancial implications for both payer and 
manufacturer. However, underlying methodologies remain poorly researched. Addi-
tionally, HTA agencies may need analytical frameworks to evaluate the value of RSS. 
METHODS: We designed a fi nancial-based agreement for a hypothetical technology. 
The fi nancial risk to be shared is defi ned as N × p × r where N is the size of the target 
patients population, p is the price/dose of the technology, r is the proportion of 
patients for whom di > D, di being the number of doses/year given to an individual 
patient i and D being the maximum number of doses/year agreed in the schemes (the 
cap). a logistic growth curve is used to simulate the risk evolution as time progresses 
and patients progressively accrue in the RSS. Multiple risk evolution and “sharing” 
scenarios with their resulting fi nancial implications for both parties are simulated. 
Finally, a Bayesian framework is introduced to allow both parties to make revisions 
as real-life information becomes available upon implementation of the RSS. RESULTS: 
For N = 1000 over a period of 3 years, D = 12 and a prior distribution for di centred 
on 12 doses but with 20% of patients receiving more than 12 doses, the model predicts 
that 23,092 doses will be delivered and that 542 doses (2.40%) will fall above the 
cap. These doses in excess determine the cost to be shared: total refund, partial refund, 
or price discount. CONCLUSIONS: Financial modelling and technological forecasting 
techniques can be combined to simulate different risk-sharing scenarios and their 
fi nancial implications for payers and manufacturers. This provides both parties with 
an analytical framework to design win-win schemes and to make potential revisions 
as real-life information becomes available.
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OBJECTIVES: The increasing use of risk-sharing in reimbursement decisions across 
major markets necessitates that key stakeholders understand the role of this concept 
in shaping drug development and regulatory decision-making. The objective of this 
research was to examine global trends in risk-sharing agreements since 1990 to 
provide a comprehensive understanding of the current and future impact of this fast-
evolving concept. METHODS: Primary research was conducted through 50 in-depth 
45-minute telephone interviews in native languages. Subjects were carefully selected 
and represented payers, government agencies, and HTA organizations in nine markets 
(Europe 5, Australia, New Zealand, United States, and Canada) to understand their 
assessment of the role which risk-sharing agreements have—or have not—played in 
their respective markets, and whether they will do so in the future. This was comple-
mented with secondary research of reimbursement decisions around the world based 
on a newly created database of risk-sharing agreements around the world. RESULTS: 
In some countries such as the United Kingdom and Italy, for certain therapeutic areas 
such as oncology, these agreements almost act as a substitute for the normal reimburse-
ment process, but primary research indicates that this practice faces signifi cant resis-
tance at many layers. Still, many other countries are seeking to understand the 
potential applicability of risk-shares to their own market. Also, risk-share agreements 
are being examined for their potential in several other therapeutic areas. While 
population- and patient-level agreements remain the most popular, we conclude that 
health outcomes-based arrangements are signifi cantly on the rise, with 27 having been 
identifi ed through the study in the markets that were studied, the majority of which 
were signed since 2007. Just over half were signed for oncology therapeutics. CON-
CLUSIONS: Outcomes-based agreements are becoming an increasingly important 
consideration to include in pricing models across the traditional development pathway 
for new molecules.
